| Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7 I Lamberto, X Liu, HS Seo, NJ Schauer, RE Iacob, W Hu, D Das, ... Cell chemical biology 24 (12), 1490-1500. e11, 2017 | 159 | 2017 |
| Advances in discovering deubiquitinating enzyme (DUB) inhibitors NJ Schauer, RS Magin, X Liu, LM Doherty, SJ Buhrlage Journal of medicinal chemistry 63 (6), 2731-2750, 2019 | 138 | 2019 |
| Deubiquitinases maintain protein homeostasis and survival of cancer cells upon glutathione depletion IS Harris, JE Endress, JL Coloff, LM Selfors, SK McBrayer, JM Rosenbluth, ... Cell metabolism 29 (5), 1166-1181. e6, 2019 | 127 | 2019 |
| Inhibition of USP10 induces degradation of oncogenic FLT3 EL Weisberg, NJ Schauer, J Yang, I Lamberto, L Doherty, S Bhatt, ... Nature chemical biology 13 (12), 1207-1215, 2017 | 111 | 2017 |
| Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism NJ Schauer, X Liu, RS Magin, LM Doherty, WC Chan, SB Ficarro, W Hu, ... Scientific reports 10 (1), 5324, 2020 | 78 | 2020 |
| Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma B Stolte, AB Iniguez, NV Dharia, AL Robichaud, AS Conway, AM Morgan, ... Journal of Experimental Medicine 215 (8), 2137-2155, 2018 | 64 | 2018 |
| Proteomics-based identification of DUB substrates using selective inhibitors JW Bushman, KA Donovan, NJ Schauer, X Liu, W Hu, AC Varca, ... Cell chemical biology 28 (1), 78-87. e3, 2021 | 30 | 2021 |
| Accelerating inhibitor discovery for deubiquitinating enzymes WC Chan, X Liu, RS Magin, NM Girardi, SB Ficarro, W Hu, ... Nature Communications 14 (1), 686, 2023 | 20 | 2023 |
| Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2 J Yang, EL Weisberg, X Liu, RS Magin, WC Chan, B Hu, NJ Schauer, ... Leukemia 36 (1), 210-220, 2022 | 14 | 2022 |
| First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring ML Granda, FA Schroeder, RHJ Borra, N Schauer, E Aisaborhale, ... American Journal of Physiology-Renal Physiology 307 (1), F116-F121, 2014 | 5 | 2014 |
| 722 Evaluation of the effects of pembrolizumab alone and in combination (s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional … K Gundle, K Rajasekaran, J Houlton, D Clayburgh, M Wagner, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | 1 | 2023 |
| Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head … K Rajasekaran, TJ Ow, CA Nathan, AL Tang, V Mehta, BA Schiff, J Pang, ... Journal of Clinical Oncology 41 (16_suppl), 2579-2579, 2023 | 1 | 2023 |
| Inhibition of USP10 Induces Degradation of Oncogenic FLT3: a novel approach to therapy of leukemia S Buhrlage, E Weisberg, N Schauer, J Yang, I Lamberto, L Doherty, ... Blood 128 (22), 524, 2016 | 1 | 2016 |
| 569 A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in … J Houlton, D Clayburgh, R Li, N Schauer, M Grenley, C Burns, A Merrell, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Abstract CT139: Intratumoral (IT) microdosing of the investigational SUMOylation Inhibitor TAK-981 in a phase 0 CIVO trial demonstrates the reactivation of type I Interferon … J Houlton, H Cash, H Xu, PL Swiecicki, K Casper, SB Chinn, ... Cancer Research 82 (12_Supplement), CT139-CT139, 2022 | | 2022 |
| A Target Class Approach to Deubiquitinase Inhibitor Discovery N Schauer Harvard University, 2019 | | 2019 |
| Target class platform accelerates deubiquitinase early discovery efforts S Buhrlage, E Weisberg, N Schauer, X Liu, J Yang, I Lamberto ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 256, 2018 | | 2018 |
| Abstract PR04: Degradation of leukemia oncogenes: A novel approach to therapy of leukemia S Buhrlage, E Weisberg, I Lamberto, J Yang, N Schauer, M Sattler, ... Clinical Cancer Research 23 (24_Supplement), PR04-PR04, 2017 | | 2017 |
| Degradation of leukemia oncogenes: A novel approach to therapy of leukemia. S Buhrlage, E Weisberg, I Lamberto, J Yang, N Schauer, M Sattler, ... CLINICAL CANCER RESEARCH 23 (24), 28-29, 2017 | | 2017 |
| Pd(IV)‐Mediated Fluorination of Arenes with [18F]F– for PET Imaging NJ Schauer, SM Carlin, H Ren, JM Hooker Radiochemical Syntheses: Further Radiopharmaceuticals for Positron Emission …, 2015 | | 2015 |
